Program
prifetrastat
Also written as “PF-07248144”, “Prifetrastat” and “prifetrastat Test 1”.
In Pfizer's pipeline, KAT6 epigenetic modifier
. Its studies are mostly in Renal Insufficiency · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Pfizer.
Furthest: phase 3, since Jul 3, 202510 company-led studies, 5 open or runningNext primary completion: Dec 8, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 105 open or running | phase 3since Jul 3, 2025 | Oct 5, 2020 | Dec 8, 2026phase 1 · NCT07721402 |
- Named in Pfizer’s own pipeline as
prifetrastat PF-07248144
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2020First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04606446 · 320 planned · United States, Australia, China and more
- Jul 3, 2025Phase 3 study in Breast NeoplasmsNCT07062965 · 400 planned · United States, Argentina, Australia and more
- Jul 17, 2025Phase 1 study in Healthy AdultsNCT07636018 · 12 enrolled · Belgium
- Aug 5, 2025Phase 1 study in Healthy AdultsNCT07117799 · 24 enrolled · United States
- Sep 25, 2025Phase 1 study in Healthy AdultsNCT07198035 · 12 enrolled · Belgium
- Nov 20, 2025Phase 1 study in Healthy Adult ParticipantsNCT07423286 · 8 enrolled · United States
- Jan 5, 2026Phase 1 study in Healthy Adult ParticipantsNCT07335419 · 12 enrolled · United States
- Jul 16, 20262 phase 1 studiesNCT07721402, NCT07731100
- Nov 5, 2026Phase 1 study in Renal InsufficiencyNCT07933848 · 24 planned · United States
Ahead
- Dec 8, 2026Primary completion: phase 1 study in Healthy ParticipantNCT07721402
- Jul 22, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT07062965
- May 21, 2028Primary completion: phase 1 study in Renal InsufficiencyNCT07933848
- Aug 27, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04606446
TargetBeta
“KAT6 epigenetic modifier”the company's pipeline, read by Claude · source
“An inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon administration, prifetrastat targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation …”NCIt, read by Claude
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| KAT6A/B Inhibitor BG-75202rule | BeOne Medicines | phase 1 | 2 |
| HRS-2189 | Jiangsu HengRui Medicine | phase 1 | 2 |
| KAT6 Inhibitor OP-3136rule | olema-pharmaceuticals-inc | phase 1 | 1 |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
| KAT6/KAT7 Inhibitor IDE574rule | ideaya-biosciences | phase 1 | 1 |
| HLX97 | Fosun Pharma | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933848Renal Insufficiency · United States | 1 | Not yet recruiting | May 21, 2028 | 24 |
| NCT07731100Healthy Adults · United States | 1 | Not yet recruiting | Sep 10, 2026 | 12 |
| NCT07721402Healthy Participant · Belgium | 1 | Recruiting | Dec 8, 2026 | 32 |
| NCT07335419Healthy Adult Participants · United States | 1 | Completed | Feb 22, 2026 | 12 |
| NCT07423286Healthy Adult Participants · United States | 1 | Completed | Dec 28, 2025 | 8 |
| NCT07198035Healthy Adults · Belgium | 1 | Completed | Dec 17, 2025 | 12 |
| NCT07117799Healthy Adults · United States | 1 | Completed | Jun 18, 2025 | 24 |
| NCT07636018Healthy Adults · Belgium | 1 | Completed | Oct 8, 2025 | 12 |
| NCT07062965Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jul 22, 2027 | 400 |
| NCT04606446Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 2 | Recruiting | Aug 27, 2029 | 320 |
How it is read
Names in the registry
- “PF-07248144”, 8 entries
- “Prifetrastat”, 2 entries
- “prifetrastat Test 1”, 1 entry
- “prifetrastat Test 2”, 1 entry
- “Oral [14C] PF-07248144”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.